Novel vitamin E analogues disrupt autocrine signalling and angiogenesis: Mechanistic studies and relevance to cancer management

新型维生素 E 类似物破坏自分泌信号和血管生成：机制研究及其与癌症管理的相关性

• 批准号: DP0667162
• 负责人: Prof Jiri Neuzil
• 金额: $ 16.49万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0667162
• 关键词: Novel; vitamin; analogues; disrupt; autocrine

Breast and mesothelioma cancers present a severe problem in Australia and many patients succumb due to lack of appropriate treatment. We believe that vitamin E analogues, selective drugs efficient against cancer cells, hold a promise as future drugs against these two pathologies. Vitamin E analogues act by several mechanisms, including toxic effect on the cancer cells and also on cells that are necessary for efficient progression of tumours, such as cells of the malignant blood vessels. Results of this project will be used to prepare clinical testing of these highly promising drugs.

乳腺癌和间皮瘤在澳大利亚是一个严重的问题，许多患者由于缺乏适当的治疗而死亡。我们相信，维生素E类似物，选择性药物有效地对抗癌细胞，持有作为未来药物对这两种病理的承诺。维生素E类似物通过几种机制起作用，包括对癌细胞的毒性作用，以及对肿瘤有效进展所必需的细胞，如恶性血管细胞的毒性作用。该项目的结果将用于准备这些非常有前途的药物的临床试验。